Navigation Links
Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System

nvolve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended March 31, 2007.

Contact

Geron
David L. Greenwood, 650-473-7765
Chief Financial Officer
info@geron.com
or
Russo Partners, LLC
David Schull, 858-717-2310 (Media)
david.schull@russopartnersllc.com
Matthew Haines, 212-845-4235 (Investors)
matthew.haines@russopartnersllc.com


'"/>




Page: 1 2 3

Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine

Post Your Comments:
(Date:12/1/2009)...ewswire-FirstCall/ -- An expert from PAREXEL Inter...lobal biopharmaceutical services provider, will le...drug development in Asia at the Partnerships in Cl...December 1-3, 2009 at the Intercontinental Hotel i...e, which is focused on maximizing efficiency and m...
(Date:11/30/2009)...0 Microban International, Ltd., th...protection, is pleased to announce their exclusive...e largest U.S. manufacturer and distributor of cer...nching two new lines of ceramic tile with OutStand...pending silver based technology, in order to creat...
(Date:11/30/2009).../ -- Breast-Specific Gamma Imaging (BSGI) has been... for the detection of ductal carcinoma in situ (DC...s a molecular breast imaging technique that can se...er very early stage cancers. According to findings...ological Society of North America (RSNA), BSGI is ...
Breaking Medicine Technology:PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 2PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 3PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 4Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology 2Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2Virus May Affect Survival in Head and Neck Cancer 53302 1Virus May Affect Survival in Head and Neck Cancer 53302 2MedQuist Reports Second Quarter 2009 Results 53297 1MedQuist Reports Second Quarter 2009 Results 53297 2MedQuist Reports Second Quarter 2009 Results 53297 3MedQuist Reports Second Quarter 2009 Results 53297 4MedQuist Reports Second Quarter 2009 Results 53297 5MedQuist Reports Second Quarter 2009 Results 53297 6MedQuist Reports Second Quarter 2009 Results 53297 7MedQuist Reports Second Quarter 2009 Results 53297 8MedQuist Reports Second Quarter 2009 Results 53297 9MedQuist Reports Second Quarter 2009 Results 53297 10Clinical Trial by Licensee Does Not Meet Primary Endpoint 53294 1Clinical Trial by Licensee Does Not Meet Primary Endpoint 53294 2
...ation approved to reduce both A1C and LDL choleste...nc.,announced that the United States Food and Drug...lesevelam HCl) to improve glycemic control,(measur...es mellitus in,combination with metformin, sulfony... with other anti-diabetic agents. Welchol is now t...
...onal Trial Published in CANCER: the Journal of the...SEATTLE, Jan. 22 Cell Therapeutics, Inc.,(CTI) (N...of a phase II,clinical study, published in the jou...immunotherapy (RIT) to chemotherapy for previously...on-Hodgkin,s lymphoma,(NHL) was both well tolerate...
Other Medicine Technology:Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 2Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 4Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 5Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 6Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 7Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 2Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 3Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 5
(Date:12/1/2009)... , SMITHFIELD, R.I., Dec. 1 /PRNewswire/... bad assumptions are hazardous and can result in i...ment regulation, a handful of persistent bad assum...ctiveness of occupational Hearing Conservation Pr... free, white paper from Howard Leight, " Bad As...
(Date:12/1/2009)..., ,, NEW YORK, Dec. 1 Ov...der in the development and delivery of customizabl... scientific and academic markets, will be showcasi...ur first-to-market cross-platform search solution,...n, based on the American Psychological Association...
(Date:12/1/2009)...GTON, Dec. 1 The follow...national Development: ,, Chairman Kerry, Rankin..., I am honored to be nominated by President Obama ...ncy for International Development, and I appreciat...Secretary of State Clinton has expressed the convi...
(Date:12/1/2009)...atient Safety Authority Encourages Older Persons a...New Consumer Tips Based Upon Authority Data ,...-- Ninety percent of all vaccine preventable death... in nursing homes, according to highlighted studie...009 December Patient Safety Advisory . ,, Acco...
(Date:12/1/2009)...ovember 2009. Performing surgical operations with...as become a reality. This is demonstrated by the r...Orifice Transluminal Endoscopy Surgery), an innova... using the body,s natural orifices. The results ar... shorter hospital stay and faster recovery. Curren...
Breaking Medicine News(10 mins):Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 2Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 3Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 2Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 4Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 5Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 6Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 7Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 8Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 9Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 4Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 5Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 3
... Berman Sobol Shapiro has begun,an investigation c...ing-Plough (NYSE: SGP ), manufacturers of Zetia a...ges of whether Merck and Schering-Plough,violated ... available,as a generic drug for about one-third o...
...and child nutrition interventions were implemented...3s could be reduced by a third, and deaths by up t...shed today. , Professor Simon Cousens, of the Lon...es, which is being launched this week. Professor C...
...6 The Ninth Annual Renal Teen,Prom, "Winter Elega..., is,to be held Sunday, January 20, 2008 at Notre ... unique event attracts more than 350 kidney teens,...n California. This year,s prom will be packed full...
... Patients are urged,to suggest candidates for Pen...atient participation is vital; many past award win...d, sponsored by the Pennsylvania Academy of Family...,members of PAFP. Candidates should serve as role ...
...n. 16 Universal,Health Services, Inc. (NYSE: UHS...ed to pay a cash dividend of $0.08 per share on Ma... 3, 2008., Universal Health Services, Inc. is one...ationwide and in Puerto Rico., Certain statements...
...ted For Misdemeanors in Clear Case of Selective,En...abian,Nunez directed the California Highway Patrol...0 miles to speak out against mandatory insurance,f...-state law requiring all residents to purchase,pri...
Other Medicine News:Health News:Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia 2Health News:Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia 3Health News:One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented 2Health News:Celebrities to Attend the Ninth Annual Kidney Teen Prom 2Health News:Nominate Your Family Doctor for Family Physician of the Year 2Health News:Uninsured Massachusetts Consumer Who Cannot Afford Mandatory Purchase of Health Insurance Flies 3,000 Miles to Speak Out; Is Thrown Out Of Capitol By Speaker Nunez 2Health News:Uninsured Massachusetts Consumer Who Cannot Afford Mandatory Purchase of Health Insurance Flies 3,000 Miles to Speak Out; Is Thrown Out Of Capitol By Speaker Nunez 3Health News:Uninsured Massachusetts Consumer Who Cannot Afford Mandatory Purchase of Health Insurance Flies 3,000 Miles to Speak Out; Is Thrown Out Of Capitol By Speaker Nunez 4
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: